• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr. Noel G. Boyle Discusses Benefits of Dabigatran Versus Warfarin for Treatment of Atrial Fibrillation

Article

Dr. Noel G. Boyle, Professor of Medicine, Ronald Reagan UCLA Medical Center, Los Angeles, talks about new medications that can work as alternatives to warfarin for atrial fibrillation patients who are at risk for stroke.

In addition, Dr. Boyle discusses the benefits of dabigatran (Brand name: Pradaxa) versus warfarin for the treatment of patients with atrial fibrillation. According to Dr. Boyle, advantages of dabigatran include no patient monitoring, fixed dosing, and less drug interactions. Disadvantages of dabigatran include twice daily dosing and no easy method for monitoring, according to Dr. Boyle.

Related Videos
Yael Mauer, MD, MPH
Pregnant Patient | image credit: pressmaster - stock.adobe.com
Amit Singal, MD, UT Southwestern Medical Center
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
Beau Raymond, MD
Binod Dhakal, MD, Medical College of Wisconsin, lead CARTITUDE-4 investigator
Dr Sophia Humphreys
Robert Zimmerman, MD
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.